|
|
 Previous Article | Table of Contents | Next Article 
Bone marrow transplantation for leukemia following a new busulfan and
cyclophosphamide regimen
PJ Tutschka, EA Copelan and JP Klein
Ohio State University Bone Marrow Transplant Program, Columbus 43210.
Busulfan 16 mg/kg and cyclophosphamide 120 mg/kg were used as conditioning
prior to allogeneic marrow transplantation in 50 adult patients with acute
nonlymphocytic leukemia (ANLL), acute lymphocytic leukemia (ALL), and
chronic myelogenous leukemia (CML). A standard risk group of 20 patients
included those with acute leukemia in remission and CML in chronic phase. A
high-risk group of 30 patients included individuals with refractory acute
leukemia, acute leukemia in relapse, acute leukemia following preleukemia,
and CML in accelerated and blastic phase. Complete remission and sustained
complete engraftment were achieved in all evaluable patients. The duration
of aplasia was remarkably short (median of 8 days), resulting in a low
infection rate during the period of neutropenia, a reduced need for blood
product support, and a short length of hospital stay. Three-year actuarial
relapse-free survival in both standard-risk (88.9% +/- 10.5%) and high-
risk (50.5% +/- 9.6%) groups compares favorably with that reported with
total body irradiation (TBI) containing regimens.
Volume 70,
Issue 5,
pp. 1382-1388,
11/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Hauser, O. Zach, O. Krieger, H. Kasparu, J. Koenig, M. Girschikofsky, R. Oberbauer, and D. Lutz
A single nucleotide polymorphism at chromosome 2q21.3 (LCT -13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation
Blood,
September 1, 2008;
112(5):
2156 - 2159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Aschan
Allogeneic haematopoietic stem cell transplantation: current status and future outlook
Br. Med. Bull.,
October 5, 2006;
(2006)
ldl005v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood,
September 1, 2004;
104(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Lima, D. Couriel, P. F. Thall, X. Wang, T. Madden, R. Jones, E. J. Shpall, M. Shahjahan, B. Pierre, S. Giralt, et al.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Blood,
August 1, 2004;
104(3):
857 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.B. Lund, L. Brinch, J. Kongerud, and J. Boe
Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide
Eur. Respir. J.,
June 1, 2004;
23(6):
901 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sackstein, J. L. Messina, and G. J. Elfenbein
In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD
Blood,
January 15, 2003;
101(2):
771 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Thornley, R. Sutherland, R. Wynn, R. Nayar, L. Sung, G. Corpus, T. Kiss, J. Lipton, J. Doyle, F. Saunders, et al.
Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss
Blood,
April 1, 2002;
99(7):
2387 - 2396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Auffermann-Gretzinger, I. S. Lossos, T. A. Vayntrub, W. Leong, F. C. Grumet, K. G. Blume, K. E. Stockerl-Goldstein, R. Levy, and J. A. Shizuru
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
Blood,
February 15, 2002;
99(4):
1442 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Thornley, D. R. Sutherland, R. Nayar, L. Sung, M. H. Freedman, and H. A. Messner
Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+CD90{-} hematopoietic progenitors
Blood,
March 15, 2001;
97(6):
1876 - 1878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Davies, N. K. C. Ramsay, J. P. Klein, D. J. Weisdorf, B. Bolwell, J.-Y. Cahn, B. M. Camitta, R. P. Gale, S. Giralt, C. Heilmann, et al.
Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
January 14, 2000;
18(2):
340 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Coco, D. Diverio, G. Avvisati, M. C. Petti, G. Meloni, E. M. Pogliani, A. Biondi, G. Rossi, C. Carlo-Stella, C. Selleri, et al.
Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
Blood,
October 1, 1999;
94(7):
2225 - 2229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Nevill, H. C. Fung, J. D. Shepherd, D. E. Horsman, S. H. Nantel, H.-G. Klingemann, D. L. Forrest, C. L. Toze, H. J. Sutherland, D. E. Hogge, et al.
Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation
Blood,
September 15, 1998;
92(6):
1910 - 1917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.C. Gorin
Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia
Blood,
August 15, 1998;
92(4):
1073 - 1090.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Meloni, D. Diverio, M. Vignetti, G. Avvisati, S. Capria, M. C. Petti, F. Mandelli, and F. Lo Coco
Autologous Bone Marrow Transplantation for Acute Promyelocytic Leukemia in Second Remission: Prognostic Relevance of Pretransplant Minimal Residual Disease Assessment by Reverse-Transcription Polymerase Chain Reaction of the PML/RARalpha Fusion Gene
Blood,
August 1, 1997;
90(3):
1321 - 1325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Deeg, D. Lin, W. Leisenring, M. Boeckh, C. Anasetti, F. R. Appelbaum, T. R. Chauncey, K. Doney, M. Flowers, P. Martin, et al.
Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial
Blood,
May 15, 1997;
89(10):
3880 - 3887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Chao, G. M. Schmidt, J. C. Niland, M. D. Amylon, A. C. Dagis, G. D. Long, A. P. Nademanee, R. S. Negrin, M. R. O'Donnell, P. M. Parker, et al.
Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease
N. Engl. J. Med.,
October 21, 1993;
329(17):
1225 - 1230.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Giralt, S. Escudier, H. Kantarjian, A. Deisseroth, E. J. Freireich, B. S. Andersson, S. O'Brien, M. Andreeff, H. Fisher, A. Cork, et al.
Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation
N. Engl. J. Med.,
September 9, 1993;
329(11):
757 - 761.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Questions and Answers
JAMA,
December 26, 1990;
264(24):
3208 - 3211.
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, J. Barrall, R. Storb, L. D. Fisher, G. Schoch, R. E. Ramberg, H. Shulman, C. Anasetti, S. I. Bearman, P. Beatty, et al.
Bone Marrow Transplantation for Patients with Myelodysplasia: Pretreatment Variables and Outcome
Ann Intern Med,
April 15, 1990;
112(8):
590 - 597.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Sureda, J. P. de Oteyza, J. G. Larana, and J. Odriozola
High-Dose Busulfan and Seizures
Ann Intern Med,
September 15, 1989;
111(6):
543 - 544.
[Abstract]
[PDF]
|
|
|
|
|
